Cargando…
Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice
We previously reported that the non-immunosuppressive cyclophilin inhibitors (CypIs)—cyclosporin A analog CRV431 and sanglifehrin analog NV556—efficiently inhibit HCV replication in vitro. In this study, we asked whether they can also reduce HCV replication in vivo. We found that a single oral admin...
Autores principales: | Bobardt, Michael, Hansson, Magnus Joakim, Mayo, Patrick, Ure, Daren, Foster, Robert, Gallay, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413547/ https://www.ncbi.nlm.nih.gov/pubmed/32764799 http://dx.doi.org/10.1371/journal.pone.0237236 |
Ejemplares similares
-
The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice
por: Gallay, Philippe, et al.
Publicado: (2019) -
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
por: Kuo, Joseph, et al.
Publicado: (2019) -
Synergistic Effects of Sanglifehrin-Based Cyclophilin Inhibitor NV651 with Cisplatin in Hepatocellular Carcinoma
por: Simón Serrano, Sonia, et al.
Publicado: (2022) -
The cyclophilin inhibitor CRV431 prevents both cyclophilin A-HBx complex formation and HBV replication
por: Foster, R.T., et al.
Publicado: (2017) -
In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B
por: Trepanier, Daniel J., et al.
Publicado: (2017)